Abstract
Radioimmunotherapy (RIT) uses monoclonal antibodies (mAb) that are labeled with a particle-emitting radioisotope to deliver damaging radiation to specific antigens on cancer cells. Since its initial development for the treatment of lymphomas, RIT strategies are now being tested in other hematological malignancies and solid tumors. RIT in solid tumors remains a difficult endeavor due to physiological differences imncluding the presence of a dynamic tumor microenvironment. Nevertheless, the interest in RIT is buoyed by the recent clinical success of mAb as cancer therapeutics, the identification of novel cancer-associated proteins, and the development of novel isotope production and radiolabeling methods. The development of new radioimmunoconjugates requires the selection of a suitable target, mAb, and radiolabeling strategies. Many targets have already been validated for RIT, and multiple strategies to improve its therapeutic index have been proposed such as combination treatments, pre-targeting strategies, or imaging with radiolabeled mAb to pre-screen patients that are potential responders.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495–7. https://doi.org/10.1038/256495a0.
Scott AM, Allison JP, Wolchok JD. Monoclonal antibodies in cancer therapy. Cancer Immun. 2012;12:14.
Dobrenkov K, Cheung N-KV. 30 – Therapeutic antibodies and immunologic conjugates. In: Niederhuber JE, Armitage JO, Kastan MB, Doroshow JH, Tepper JE, editors. Abeloff’s clinical oncology. 6th ed. Philadelphia: Sanders; 2020. p. 486–99. e8.
Goldenberg DM, DeLand F, Kim E, Bennett S, Primus FJ, van Nagell JR Jr, et al. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med. 1978;298(25):1384–6. https://doi.org/10.1056/NEJM197806222982503.
Mach JP, Buchegger F, Forni M, Ritschard J, Berche C, Lumbroso JD, et al. Use of radiolabelled monoclonal anti-CEA antibodies for the detection of human carcinomas by external photoscanning and tomoscintigraphy. Immunol Today. 1981;2(12):239–49. https://doi.org/10.1016/0167-5699(81)90011-6.
Barbet J, Bardies M, Bourgeois M, Chatal JF, Cherel M, Davodeau F, et al. Radiolabeled antibodies for cancer imaging and therapy. Methods Mol Biol. 2012;907:681–97. https://doi.org/10.1007/978-1-61779-974-7_38.
Shimoni A, Zwas ST. Radioimmunotherapy and autologous stem-cell transplantation in the treatment of B-cell non-Hodgkin lymphoma. Semin Nucl Med. 2016;46(2):119–25. https://doi.org/10.1053/j.semnuclmed.2015.10.009.
Sharkey RM, Behr TM, Mattes MJ, Stein R, Griffiths GL, Shih LB, et al. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22. Cancer Immunol Immunother. 1997;44(3):179–88.
DeNardo GL, DeNardo SJ, O'Donnell RT, Kroger LA, Kukis DL, Meares CF, et al. Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin’s lymphoma. Clin Lymphoma. 2000;1(2):118–26.
Schroff RW, Foon KA, Beatty SM, Oldham RK, Morgan AC Jr. Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res. 1985;45(2):879–85.
van der Linden EF, van Kroonenburgh MJ, Pauwels EK. Side-effects of monoclonal antibody infusions for the diagnosis and treatment of cancer. Int J Biol Markers. 1988;3(3):147–53.
Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. 1997;57(17):3629–34.
Sodee DB, Malguria N, Faulhaber P, Resnick MI, Albert J, Bakale G. Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. ProstaScint Imaging Centers Urol. 2000;56(6):988–93.
Han M, Partin AW. Current clinical applications of the in-capromab Pendetide scan (ProstaScint(R) scan, Cyt-356). Rev Urol. 2001;3(4):165–71.
Vivier D, Sharma SK, Zeglis BM. Understanding the in vivo fate of radioimmunoconjugates for nuclear imaging. J Labelled Comp Radiopharm. 2018;61(9):672–92. https://doi.org/10.1002/jlcr.3628.
Carrasquillo JA, Mulshine JL, Bunn PA Jr, Reynolds JC, Foon KA, Schroff RW, et al. Indium-111 T101 monoclonal antibody is superior to iodine-131 T101 in imaging of cutaneous T-cell lymphoma. J Nucl Med. 1987;28(3):281–7.
Rizzieri D. Zevalin((R)) (ibritumomab tiuxetan): after more than a decade of treatment experience, what have we learned? Crit Rev Oncol Hematol. 2016;105:5–17. https://doi.org/10.1016/j.critrevonc.2016.07.008.
Teillaud JL. Engineering of monoclonal antibodies and antibody-based fusion proteins: successes and challenges. Expert Opin Biol Ther. 2005;5(Suppl 1):S15–27. https://doi.org/10.1517/14712598.5.1.S15.
Wei W, Rosenkrans ZT, Liu J, Huang G, Luo Q-Y, Cai W. ImmunoPET: concept, design, and applications. Chem Rev. 2020;120(8):3787–851. https://doi.org/10.1021/acs.chemrev.9b00738.
McKnight BN, Viola-Villegas NT. (89)Zr-ImmunoPET companion diagnostics and their impact in clinical drug development. J Labelled Comp Radiopharm. 2018;61(9):727–38. https://doi.org/10.1002/jlcr.3605.
Beck A, Dumontet C, Joubert N. Antibody-drug conjugates in oncology. Recent success of an ancient concept. Med Sci (Paris). 2019;35(12):1034–42. https://doi.org/10.1051/medsci/2019227.
Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer. 2012;12(4):278–87. https://doi.org/10.1038/nrc3236.
Bailly C, Bodet-Milin C, Guérard F, Rousseau C, Chérel M, Kraeber-Bodéré F, et al. Prospects for enhancing efficacy of Radioimmunotherapy. In: Hosono M, Chatal J-F, editors. Resistance to Ibritumomab in lymphoma. Cham: Springer International Publishing; 2018. p. 139–53.
Ricart AD. Immunoconjugates against solid tumors: mind the gap. Clin Pharmacol Ther. 2011;89(4):513–23. https://doi.org/10.1038/clpt.2011.8.
Slastnikova TA, Ulasov AV, Rosenkranz AA, Sobolev AS. Targeted intracellular delivery of antibodies: the state of the art. Front Pharmacol. 2018;9:1208. https://doi.org/10.3389/fphar.2018.01208.
Poty S, Mandleywala K, O'Neill E, Knight JC, Cornelissen B, Lewis JS. (89)Zr-PET imaging of DNA double-strand breaks for the early monitoring of response following alpha- and beta-particle radioimmunotherapy in a mouse model of pancreatic ductal adenocarcinoma. Theranostics. 2020;10(13):5802–14. https://doi.org/10.7150/thno.44772.
Carmon KS, Azhdarinia A. Application of immuno-PET in antibody-drug conjugate development. Mol Imaging. 2018;17:1536012118801223. https://doi.org/10.1177/1536012118801223.
Wu AM. Engineered antibodies for molecular imaging of cancer. Methods. 2014;65(1):139–47. https://doi.org/10.1016/j.ymeth.2013.09.015.
Aerts HJ, Dubois L, Perk L, Vermaelen P, van Dongen GA, Wouters BG, et al. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med. 2009;50(1):123–31. https://doi.org/10.2967/jnumed.108.054312.
Colombo I, Overchuk M, Chen J, Reilly RM, Zheng G, Lheureux S. Molecular imaging in drug development: update and challenges for radiolabeled antibodies and nanotechnology. Methods. 2017;130:23–35. https://doi.org/10.1016/j.ymeth.2017.07.018.
Moek KL, Giesen D, Kok IC, de Groot DJA, Jalving M, Fehrmann RSN, et al. Theranostics using antibodies and antibody-related therapeutics. J Nucl Med. 2017;58(Suppl 2):83S–90S. https://doi.org/10.2967/jnumed.116.186940.
Chiavenna SM, Jaworski JP, Vendrell A. State of the art in anti-cancer mAbs. J Biomed Sci. 2017;24(1):15. https://doi.org/10.1186/s12929-016-0311-y.
Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacometrics Syst Pharmacol. 2017;6(9):576–88. https://doi.org/10.1002/psp4.12224.
Cui Y, Cui P, Chen B, Li S, Guan H. Monoclonal antibodies: formulations of marketed products and recent advances in novel delivery system. Drug Dev Ind Pharm. 2017;43(4):519–30. https://doi.org/10.1080/03639045.2017.1278768.
Boyiadzis M, Foon KA. Approved monoclonal antibodies for cancer therapy. Expert Opin Biol Ther. 2008;8(8):1151–8. https://doi.org/10.1517/14712598.8.8.1151.
Nimmagadda S, Shelake S, Pomper MG. Preclinical experimentation in oncology. In: Lewis JS, Windhorst AD, Zeglis BM, editors. Radiopharmaceutical chemistry. Cham: Springer International Publishing; 2019. p. 569–82.
Dimastromatteo J, Kelly KA. Target identification, lead discovery, and optimization. In: Lewis JS, Windhorst AD, Zeglis BM, editors. Radiopharmaceutical chemistry. Cham: Springer International Publishing; 2019. p. 555–67.
Beraud E, Collignon A, Franceschi C, Olive D, Lombardo D, Mas E. Investigation of a new tumor-associated glycosylated antigen as target for dendritic cell vaccination in pancreatic cancer. Onco Targets Ther. 2012;1(1):56–61. https://doi.org/10.4161/onci.1.1.18459.
Vankemmelbeke M, Chua JX, Durrant LG. Cancer cell associated glycans as targets for immunotherapy. Onco Targets Ther. 2016;5(1):e1061177. https://doi.org/10.1080/2162402X.2015.1061177.
Lu Z, Kamat K, Johnson BP, Yin CC, Scholler N, Abbott KL. Generation of a fully human scFv that binds tumor-specific Glycoforms. Sci Rep. 2019;9(1):5101. https://doi.org/10.1038/s41598-019-41567-6.
Hakomori S. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci U S A. 2002;99(16):10231–3. https://doi.org/10.1073/pnas.172380699.
Hauselmann I, Borsig L. Altered tumor-cell glycosylation promotes metastasis. Front Oncol. 2014;4:28. https://doi.org/10.3389/fonc.2014.00028.
Schietinger A, Philip M, Schreiber H. Specificity in cancer immunotherapy. Semin Immunol. 2008;20(5):276–85. https://doi.org/10.1016/j.smim.2008.07.001.
Chiu ML, Goulet DR, Teplyakov A, Gilliland GL. Antibody structure and function: the basis for engineering therapeutics. Antibodies (Basel). 2019;8(4). https://doi.org/10.3390/antib8040055.
Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520. https://doi.org/10.3389/fimmu.2014.00520.
Hoffmann RM, Coumbe BGT, Josephs DH, Mele S, Ilieva KM, Cheung A, et al. Antibody structure and engineering considerations for the design and function of antibody drug conjugates (ADCs). Onco Targets Ther. 2018;7(3):e1395127. https://doi.org/10.1080/2162402X.2017.1395127.
Irani V, Guy AJ, Andrew D, Beeson JG, Ramsland PA, Richards JS. Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases. Mol Immunol. 2015;67(2, Part A):171–82. https://doi.org/10.1016/j.molimm.2015.03.255.
Stern M, Herrmann R. Overview of monoclonal antibodies in cancer therapy: present and promise. Crit Rev Oncol Hematol. 2005;54(1):11–29. https://doi.org/10.1016/j.critrevonc.2004.10.011.
Weiner LM. Fully human therapeutic monoclonal antibodies. J Immunother. 2006;29(1):1–9. https://doi.org/10.1097/01.cji.0000192105.24583.83.
Harding FA, Stickler MM, Razo J, DuBridge RB. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs. 2010;2(3):256–65. https://doi.org/10.4161/mabs.2.3.11641.
Gómez Román VR, Murray JC, Weiner LM. Chapter 1 - antibody-dependent cellular cytotoxicity (ADCC). In: Ackerman ME, Nimmerjahn F, editors. Antibody Fc. Boston: Academic Press; 2014. p. 1–27.
Weiskopf K, Weissman IL. Macrophages are critical effectors of antibody therapies for cancer. MAbs. 2015;7(2):303–10. https://doi.org/10.1080/19420862.2015.1011450.
Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol. 2005;23(9):1147–57. https://doi.org/10.1038/nbt1137.
Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(8):493–507. https://doi.org/10.2165/11531280-000000000-00000.
Liu L. Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and fc-fusion proteins. J Pharm Sci. 2015;104(6):1866–84. https://doi.org/10.1002/jps.24444.
Ovacik M, Lin K. Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development. Clin Transl Sci. 2018;11(6):540–52. https://doi.org/10.1111/cts.12567.
Cataldi M, Vigliotti C, Mosca T, Cammarota M, Capone D. Emerging role of the spleen in the pharmacokinetics of monoclonal antibodies, nanoparticles and exosomes. Int J Mol Sci. 2017;18(6) https://doi.org/10.3390/ijms18061249.
Batra SK, Jain M, Wittel UA, Chauhan SC, Colcher D. Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr Opin Biotechnol. 2002;13(6):603–8.
Senter PD. Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol. 2009;13(3):235–44. https://doi.org/10.1016/j.cbpa.2009.03.023.
Tolcher AW, Sugarman S, Gelmon KA, Cohen R, Saleh M, Isaacs C, et al. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J Clin Oncol. 1999;17(2):478–84. https://doi.org/10.1200/JCO.1999.17.2.478.
Juweid M, Neumann R, Paik C, Perez-Bacete MJ, Sato J, van Osdol W, et al. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res. 1992;52(19):5144–53.
Weinstein JN, van Osdol W. Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the "binding site barrier". Cancer Res. 1992;52(9 Suppl):2747s–51s.
Rudnick SI, Adams GP. Affinity and avidity in antibody-based tumor targeting. Cancer Biother Radiopharm. 2009;24(2):155–61. https://doi.org/10.1089/cbr.2009.0627.
Thurber GM, Schmidt MM, Wittrup KD. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev. 2008;60(12):1421–34. https://doi.org/10.1016/j.addr.2008.04.012.
Thurber GM, Schmidt MM, Wittrup KD. Factors determining antibody distribution in tumors. Trends Pharmacol Sci. 2008;29(2):57–61. https://doi.org/10.1016/j.tips.2007.11.004.
Wittrup KD, Thurber GM, Schmidt MM, Rhoden JJ. Practical theoretic guidance for the design of tumor-targeting agents. Methods Enzymol. 2012;503:255–68. https://doi.org/10.1016/B978-0-12-396962-0.00010-0.
Sharkey RM, Press OW, Goldenberg DM. A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy. Blood. 2009;113(17):3891–5. https://doi.org/10.1182/blood-2008-11-188896.
Mattes MJ, Sharkey RM, Karacay H, Czuczman MS, Goldenberg DM. Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab). Clin Cancer Res. 2008;14(19):6154–60. https://doi.org/10.1158/1078-0432.CCR-08-0404.
Sharma SK, Chow A, Monette S, Vivier D, Pourat J, Edwards KJ, et al. Fc-mediated anomalous biodistribution of therapeutic antibodies in Immunodeficient mouse models. Cancer Res. 2018;78(7):1820–32. https://doi.org/10.1158/0008-5472.CAN-17-1958.
Bhattacharyya S, Dixit M. Metallic radionuclides in the development of diagnostic and therapeutic radiopharmaceuticals. Dalton Trans. 2011;40(23):6112–28. https://doi.org/10.1039/c1dt10379b.
Wolf W, Shani J. Criteria for the selection of the most desirable radionuclide for radiolabeling monoclonal antibodies. Int J Radiation Appl Instrum Part B, Nucl Med Biol. 1986;13(4):319–24.
Boros E, Holland JP. Chemical aspects of metal ion chelation in the synthesis and application antibody-based radiotracers. J Labelled Comp Radiopharm. 2018;61(9):652–71. https://doi.org/10.1002/jlcr.3590.
Kraeber-Bodere F, Rousseau C, Bodet-Milin C, Mathieu C, Guerard F, Frampas E, et al. Tumor immunotargeting using innovative radionuclides. Int J Mol Sci. 2015;16(2):3932–54. https://doi.org/10.3390/ijms16023932.
Pouget JP, Navarro-Teulon I, Bardies M, Chouin N, Cartron G, Pelegrin A, et al. Clinical radioimmunotherapy—the role of radiobiology. Nat Rev Clin Oncol. 2011;8(12):720–34. https://doi.org/10.1038/nrclinonc.2011.160.
Mikolajczak R, van der Meulen NP, Lapi SE. Radiometals for imaging and theranostics, current production and future perspectives. J Labelled Comp Radiopharm. 2019; https://doi.org/10.1002/jlcr.3770.
Wilbur DS. The radiopharmaceutical chemistry of alpha-emitting radionuclides. In: Lewis JS, Windhorst AD, Zeglis BM, editors. Radiopharmaceutical chemistry. Cham: Springer International Publishing; 2019. p. 409–24.
Tolmachev V, Orlova A, Andersson K. Methods for radiolabelling of monoclonal antibodies. Methods Mol Biol. 2014;1060:309–30. https://doi.org/10.1007/978-1-62703-586-6_16.
Martins CD, Kramer-Marek G, Oyen WJG. Radioimmunotherapy for delivery of cytotoxic radioisotopes: current status and challenges. Expert Opin Drug Deliv. 2018;15(2):185–96. https://doi.org/10.1080/17425247.2018.1378180.
Wester DW, Steele RT, Rinehart DE, DesChane JR, Carson KJ, Rapko BM, et al. Large-scale purification of 90Sr from nuclear waste materials for production of 90Y, a therapeutic medical radioisotope. Appl Radiation Isotopes. 2003;59(1):35–41.
Chakravarty R, Chakraborty S, Sarma HD, Nair KV, Rajeswari A, Dash A. (90) Y/(177) Lu-labelled Cetuximab immunoconjugates: radiochemistry optimization to clinical dose formulation. J Labelled Comp Radiopharm. 2016;59(9):354–63. https://doi.org/10.1002/jlcr.3413.
Papi S, Martano L, Garaboldi L, Rossi A, Cremonesi M, Grana CM, et al. Radiolabeling optimization and reduced staff radiation exposure for high-dose 90Y-ibritumomab tiuxetan (HD-Zevalin). Nucl Med Biol. 2010;37(1):85–93. https://doi.org/10.1016/j.nucmedbio.2009.08.012.
Kassis AI. Therapeutic radionuclides: biophysical and radiobiologic principles. Semin Nucl Med. 2008;38(5):358–66. https://doi.org/10.1053/j.semnuclmed.2008.05.002.
Kuo WI, Cheng KH, Chang YJ, Wu TT, Hsu WC, Chen LC, et al. Radiolabeling, characteristics and NanoSPECT/CT Imaging of 188Re-cetuximab in NCI-H292 human lung cancer xenografts. Anticancer Res. 2019;39, 183(1):–190. https://doi.org/10.21873/anticanres.13096.
Vallabhajosula S, Nikolopoulou A, Jhanwar YS, Kaur G, Tagawa ST, Nanus DM, et al. Radioimmunotherapy of metastatic prostate cancer with (1)(7)(7)Lu-DOTAhuJ591 anti prostate specific membrane antigen specific monoclonal antibody. Curr Radiopharm. 2016;9(1):44–53.
Yong KJ, Milenic DE, Baidoo KE, Brechbiel MW. Mechanisms of cell killing response from Low Linear Energy Transfer (LET) radiation originating from (177)Lu radioimmunotherapy targeting disseminated intraperitoneal tumor xenografts. Int J Mol Sci. 2016;17(5) https://doi.org/10.3390/ijms17050736.
Muller C, Bunka M, Haller S, Koster U, Groehn V, Bernhardt P, et al. Promising prospects for 44Sc-/47Sc-based theragnostics: application of 47Sc for radionuclide tumor therapy in mice. J Nucl Med. 2014;55(10):1658–64. https://doi.org/10.2967/jnumed.114.141614.
Novak-Hofer I, Schubiger PA. Copper-67 as a therapeutic nuclide for radioimmunotherapy. Eur J Nucl Med Mol Imaging. 2002;29(6):821–30. https://doi.org/10.1007/s00259-001-0724-y.
Dash A, Pillai MR, Knapp FF Jr. Production of (177)Lu for targeted radionuclide therapy: available options. Nucl Med Mol Imaging. 2015;49(2):85–107. https://doi.org/10.1007/s13139-014-0315-z.
Guleria M, Das T, Kumar C, Amirdhanayagam J, Sarma HD, Banerjee S. Preparation of clinical-scale (177) Lu-rituximab: optimization of protocols for conjugation, radiolabeling, and freeze-dried kit formulation. J Labelled Comp Radiopharm. 2017;60(5):234–41. https://doi.org/10.1002/jlcr.3493.
Frost SH, Frayo SL, Miller BW, Orozco JJ, Booth GC, Hylarides MD, et al. Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models. PLoS One. 2015;10(3):e0120561. https://doi.org/10.1371/journal.pone.0120561.
Orozco JJ, Balkin ER, Gooley TA, Kenoyer A, Hamlin DK, Wilbur DS, et al. Anti-CD45 radioimmunotherapy with 90Y but not 177Lu is effective treatment in a syngeneic murine leukemia model. PLoS One. 2014;9(12):e113601. https://doi.org/10.1371/journal.pone.0113601.
de Jong M, Breeman WA, Valkema R, Bernard BF, Krenning EP. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs. J Nucl Med. 2005;46(Suppl 1):13s–7s.
Guerard F, Barbet J, Chatal JF, Kraeber-Bodere F, Cherel M, Haddad F. Which radionuclide, carrier molecule and clinical indication for alpha-immunotherapy? Q J Nucl Med Mol Imaging. 2015;59(2):161–7.
Wild D, Frischknecht M, Zhang H, Morgenstern A, Bruchertseifer F, Boisclair J, et al. Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN). Cancer Res. 2011;71(3):1009–18. https://doi.org/10.1158/0008-5472.CAN-10-1186.
Heskamp S, Hernandez R, Molkenboer-Kuenen JDM, Essler M, Bruchertseifer F, Morgenstern A, et al. Alpha- versus beta-emitting radionuclides for pretargeted radioimmunotherapy of carcinoembryonic antigen-expressing human colon cancer xenografts. J Nucl Med. 2017;58(6):926–33. https://doi.org/10.2967/jnumed.116.187021.
Marcu L, Bezak E, Allen BJ. Global comparison of targeted alpha vs targeted beta therapy for cancer: in vitro, in vivo and clinical trials. Crit Rev Oncol Hematol. 2018;123:7–20. https://doi.org/10.1016/j.critrevonc.2018.01.001.
McDevitt MR, Barendswaard E, Ma D, Lai L, Curcio MJ, Sgouros G, et al. An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res. 2000;60(21):6095–100.
McDevitt MR, Sgouros G, Sofou S. Targeted and nontargeted alpha-particle therapies. Annu Rev Biomed Eng. 2018;20:73–93. https://doi.org/10.1146/annurev-bioeng-062117-120931.
Qiu H, Santos EB, Storb RF, Hamlin DK, Wilbur DS, Sandmaier BM. Addition of astatine-211-labeled anti-CD45 antibody to Total Body Irradiation (TBI) As conditioning for DLA-identical marrow transplantation: a novel strategy to overcome graft rejection in a canine presensitization model. Blood. 2016;128(22):2152.
Green DJ, Shadman M, Jones JC, Frayo SL, Kenoyer AL, Hylarides MD, et al. Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model. Blood. 2015;125(13):2111–9. https://doi.org/10.1182/blood-2014-11-612770.
Zalutsky MR, Pruszynski M. Astatine-211: production and availability. Curr Radiopharm. 2011;4(3):177–85.
Griswold JR, Medvedev DG, Engle JW, Copping R, Fitzsimmons JM, Radchenko V, et al. Large scale accelerator production of (225)Ac: effective cross sections for 78-192MeV protons incident on (232)Th targets. Appl Radiat Isot. 2016;118:366–74. https://doi.org/10.1016/j.apradiso.2016.09.026.
Robertson AKH, Ramogida CF, Schaffer P, Radchenko V. Development of (225)ac radiopharmaceuticals: TRIUMF perspectives and experiences. Curr Radiopharm. 2018;11(3):156–72. https://doi.org/10.2174/1874471011666180416161908.
Jurcic JG. Clinical studies with Bismuth-213 and Actinium-225 for hematologic malignancies. Curr Radiopharm. 2018;11(3):192–9. https://doi.org/10.2174/1874471011666180525102814.
Jurcic JG, Rosenblat TL. Targeted alpha-particle immunotherapy for acute myeloid leukemia. Am Soc Clin Oncol Educ Book. 2014:e126–31. https://doi.org/10.14694/EdBook_AM.2014.34.e126.
Jurcic JG. Radioimmunotherapy for hematopoietic cell transplantation. Immunotherapy. 2013;5(4):383–94. https://doi.org/10.2217/imt.13.11.
Hnatowich DJ. Recent developments in the radiolabeling of antibodies with iodine, indium, and technetium. Semin Nucl Med. 1990;20(1):80–91.
Halpern SE. The advantages and limits of indium-111 labeling of antibodies. Experimental studies and clinical applications. Int J Rad Appl Instrum B. 1986;13(2):195–201.
Speth PAJ, Kinsella TJ, Chang AE, Klecker RW Jr, Belanger K, Collins JM. Selective incorporation of iododeoxyuridine into DNA of hepatic metastases versus normal human liver. Clin Pharmacol Ther. 1988;44(4):369–75. https://doi.org/10.1038/clpt.1988.166.
Cornelissen BA, Vallis K. Targeting the nucleus: an overview of auger-electron radionuclide therapy. Curr Drug Discov Technol. 2010;7(4):263–79. https://doi.org/10.2174/157016310793360657.
Emrich JG, Brady LW, Quang TS, Class R, Miyamoto C, Black P, et al. Radioiodinated (I-125) monoclonal antibody 425 in the treatment of high grade glioma patients: ten-year synopsis of a novel treatment. Am J Clin Oncol. 2002;25(6):541–6.
Kim JH, Li L, Quang TS, Emrich JG, Yaeger TE, Jenrette JM, et al. Phase II trial of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of anaplastic astrocytoma. J Radiat Oncol. 2013;2(1):7–13. https://doi.org/10.1007/s13566-012-0071-6.
Costantini DL, Chan C, Cai Z, Vallis KA, Reilly RM. (111)in-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J Nucl Med. 2007;48(8):1357–68. https://doi.org/10.2967/jnumed.106.037937.
Pouget JP, Santoro L, Raymond L, Chouin N, Bardiès M, Bascoul-Mollevi C, et al. Cell membrane is a more sensitive target than cytoplasm to dense ionization produced by auger electrons. Radiat Res. 2008;170(2):192–200. https://doi.org/10.1667/rr1359.1.
Price EW, Orvig C. Matching chelators to radiometals for radiopharmaceuticals. Chem Soc Rev. 2014;43(1):260–90. https://doi.org/10.1039/c3cs60304k.
Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods. 1984;72(1):77–89.
Larson SM, Carrasquillo JA, Cheung NK, Press OW. Radioimmunotherapy of human tumours. Nat Rev Cancer. 2015;15(6):347–60. https://doi.org/10.1038/nrc3925.
Adumeau P, Sharma SK, Brent C, Zeglis BM. Site-specifically labeled immunoconjugates for molecular imaging--part 1: cysteine residues and Glycans. Mol Imaging Biol. 2016;18(1):1–17. https://doi.org/10.1007/s11307-015-0919-4.
Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res. 2008;41(1):98–107. https://doi.org/10.1021/ar700108g.
McCombs JR, Owen SC. Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry. AAPS J. 2015;17(2):339–51. https://doi.org/10.1208/s12248-014-9710-8.
Morais M, Ma MT. Site-specific chelator-antibody conjugation for PET and SPECT imaging with radiometals. Drug Discov Today Technol. 2018;30:91–104. https://doi.org/10.1016/j.ddtec.2018.10.002.
Kukis DL, DeNardo GL, DeNardo SJ, Mirick GR, Miers LA, Greiner DP, et al. Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates. Cancer Res. 1995;55(4):878–84.
Sharma SK, Glaser JM, Edwards KJ, Khozeimeh Sarbisheh E, Salih AK, Lewis JS, et al. A systematic evaluation of antibody modification and (89)Zr-radiolabeling for optimized Immuno-PET. Bioconjug Chem. 2020; https://doi.org/10.1021/acs.bioconjchem.0c00087.
Vosjan MJ, Perk LR, Visser GW, Budde M, Jurek P, Kiefer GE, et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat Protoc. 2010;5(4):739–43. https://doi.org/10.1038/nprot.2010.13.
Christie RJ, Tiberghien AC, Du Q, Bezabeh B, Fleming R, Shannon A, et al. Pyrrolobenzodiazepine antibody-drug conjugates designed for stable thiol conjugation. Antibodies (Basel). 2017;6(4) https://doi.org/10.3390/antib6040020.
Sussman D, Westendorf L, Meyer DW, Leiske CI, Anderson M, Okeley NM, et al. Engineered cysteine antibodies: an improved antibody-drug conjugate platform with a novel mechanism of drug-linker stability. Protein Eng Des Sel. 2018;31(2):47–54. https://doi.org/10.1093/protein/gzx067.
Adumeau P, Davydova M, Zeglis BM. Thiol-reactive bifunctional chelators for the creation of site-selectively modified radioimmunoconjugates with improved stability. Bioconjug Chem. 2018;29(4):1364–72. https://doi.org/10.1021/acs.bioconjchem.8b00081.
Maguire RT, Pascucci VL, Maroli AN, Gulfo JV. Immunoscintigraphy in patients with colorectal, ovarian, and prostate cancer. Results with site-specific immunoconjugates. Cancer. 1993;72(11 Suppl):3453–62.
Zeglis BM, Davis CB, Aggeler R, Kang HC, Chen A, Agnew BJ, et al. Enzyme-mediated methodology for the site-specific radiolabeling of antibodies based on catalyst-free click chemistry. Bioconjug Chem. 2013;24(6):1057–67. https://doi.org/10.1021/bc400122c.
Anami Y, Tsuchikama K. Transglutaminase-mediated conjugations. Methods Mol Biol. 2020;2078:71–82. https://doi.org/10.1007/978-1-4939-9929-3_5.
Jeger S, Zimmermann K, Blanc A, Grunberg J, Honer M, Hunziker P, et al. Site-specific and stoichiometric modification of antibodies by bacterial transglutaminase. Angew Chem. 2010;49(51):9995–7. https://doi.org/10.1002/anie.201004243.
Wu Y, Zhu H, Zhang B, Liu F, Chen J, Wang Y, et al. Synthesis of site-specific radiolabeled antibodies for radioimmunotherapy via genetic code expansion. Bioconjug Chem. 2016;27(10):2460–8. https://doi.org/10.1021/acs.bioconjchem.6b00412.
Adumeau P, Sharma SK, Brent C, Zeglis BM. Site-specifically labeled immunoconjugates for molecular imaging—part 2: peptide tags and unnatural amino acids. Mol Imaging Biol. 2016;18(2):153–65. https://doi.org/10.1007/s11307-015-0920-y.
Fay R, Holland JP. The impact of emerging bioconjugation chemistries on radiopharmaceuticals. J Nucl Med. 2019;60(5):587–91. https://doi.org/10.2967/jnumed.118.220806.
Beck A, Goetsch L, Dumontet C, Corvaia N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315–37. https://doi.org/10.1038/nrd.2016.268.
Falck G, Müller KM. Enzyme-based labeling strategies for antibody–drug conjugates and antibody mimetics. Antibodies. 2018;7(1):4.
Tsuchikama K, An Z. Antibody-drug conjugates: recent advances in conjugation and linker chemistries. Protein Cell. 2018;9(1):33–46. https://doi.org/10.1007/s13238-016-0323-0.
Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol. 2005;23(21):4591–601. https://doi.org/10.1200/JCO.2005.05.160.
Kim SH. Is radioimmunotherapy a 'magic bullet'? Korean J Hematol. 2012;47(2):85–6. https://doi.org/10.5045/kjh.2012.47.2.85.
Chamarthy MR, Williams SC, Moadel RM. Radioimmunotherapy of non-Hodgkin’s lymphoma: from the ‘magic bullets’ to ‘radioactive magic bullets’. Yale J Biol Med. 2011;84(4):391–407.
Janiak MK, Wincenciak M, Cheda A, Nowosielska EM, Calabrese EJ. Cancer immunotherapy: how low-level ionizing radiation can play a key role. Cancer Immunol Immunother. 2017;66(7):819–32. https://doi.org/10.1007/s00262-017-1993-z.
Gorin JB, Menager J, Gouard S, Maurel C, Guilloux Y, Faivre-Chauvet A, et al. Antitumor immunity induced after alpha irradiation. Neoplasia. 2014;16(4):319–28. https://doi.org/10.1016/j.neo.2014.04.002.
Gorin JB, Guilloux Y, Morgenstern A, Cherel M, Davodeau F, Gaschet J. Using alpha radiation to boost cancer immunity? Onco Targets Ther. 2014;3(9):e954925. https://doi.org/10.4161/21624011.2014.954925.
Wilderman SJ, Roberson PL, Bolch WE, Dewaraja YK. Investigation of effect of variations in bone fraction and red marrow cellularity on bone marrow dosimetry in radio-immunotherapy. Phys Med Biol. 2013;58(14):4717–31. https://doi.org/10.1088/0031-9155/58/14/4717.
Sgouros G. Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. J Nucl Med. 1993;34(4):689–94.
Vallabhajosula S, Goldsmith SJ, Hamacher KA, Kostakoglu L, Konishi S, Milowski MI, et al. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. J Nucl Med. 2005;46(5):850–8.
Dainiak N. Hematologic consequences of exposure to ionizing radiation. Exp Hematol. 2002;30(6):513–28.
Baechler S, Hobbs RF, Jacene HA, Bochud FO, Wahl RL, Sgouros G. Predicting hematologic toxicity in patients undergoing radioimmunotherapy with 90Y-ibritumomab tiuxetan or 131I-tositumomab. J Nucl Med. 2010;51(12):1878–84. https://doi.org/10.2967/jnumed.110.079947.
Sas N, Rousseau J, Nguyen F, Bellec E, Larrsson E, Becavin S, et al. A compartmental model of mouse thrombopoiesis and erythropoiesis to predict bone marrow toxicity after internal irradiation. J Nucl Med. 2014;55(8):1355–60. https://doi.org/10.2967/jnumed.113.133330.
Peyrade F, Triby C, Slama B, Fontana X, Gressin R, Broglia JM, et al. Radioimmunotherapy in relapsed follicular lymphoma previously treated by autologous bone marrow transplant: a report of eight new cases and literature review. Leuk Lymphoma. 2008;49(9):1762–8. https://doi.org/10.1080/10428190802273278.
Cheson BD. Radioimmunotherapy of non-Hodgkin’s lymphomas. Curr Drug Targets. 2006;7(10):1293–300.
Kraeber-Bodere F, Bodet-Milin C, Rousseau C, Eugene T, Pallardy A, Frampas E, et al. Radioimmunoconjugates for the treatment of cancer. Semin Oncol. 2014;41(5):613–22. https://doi.org/10.1053/j.seminoncol.2014.07.004.
Navarro-Teulon I, Lozza C, Pelegrin A, Vives E, Pouget JP. General overview of radioimmunotherapy of solid tumors. Immunotherapy. 2013;5(5):467–87. https://doi.org/10.2217/imt.13.34.
Song H, Sgouros G. Radioimmunotherapy of solid tumors: searching for the right target. Curr Drug Deliv. 2011;8(1):26–44.
Bartholoma MD. Radioimmunotherapy of solid tumors: approaches on the verge of clinical application. J Labelled Comp Radiopharm. 2018; https://doi.org/10.1002/jlcr.3619.
Bodet-Milin C, Ferrer L, Pallardy A, Eugene T, Rauscher A, Alain F-C, et al. Radioimmunotherapy of B-cell non-Hodgkin’s lymphoma. Front Oncol. 2013;3:177. https://doi.org/10.3389/fonc.2013.00177.
Bodet-Milin C, Kraeber-Bodere F, Eugene T, Guerard F, Gaschet J, Bailly C, et al. Radioimmunotherapy for treatment of acute leukemia. Semin Nucl Med. 2016;46(2):135–46. https://doi.org/10.1053/j.semnuclmed.2015.10.007.
Rezaei A, Adib M, Mokarian F, Tebianian M, Nassiri R. Leukemia markers expression of peripheral blood vs bone marrow blasts using flow cytometry. Med Sci Monit. 2003;9(8):CR359–62.
Goldenberg DM. Some like it hot: lymphoma radioimmunotherapy. Blood. 2009;113(20):4823–4. https://doi.org/10.1182/blood-2009-02-203166.
Santos MAO, Lima MM. CD20 role in pathophysiology of Hodgkin’s disease. Rev Assoc Med Bras. 2017;63(9):810–3. https://doi.org/10.1590/1806-9282.63.09.810.
Shanehbandi D, Majidi J, Kazemi T, Baradaran B, Aghebati-Maleki L. CD20-based immunotherapy of B-cell derived hematologic malignancies. Curr Cancer Drug Targets. 2017;17(5):423–44. https://doi.org/10.2174/1568009617666170109151128.
Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today. 1994;15(9):450–4. https://doi.org/10.1016/0167-5699(94)90276-3.
Read ED, Eu P, Little PJ, Piva TJ. The status of radioimmunotherapy in CD20+ non-Hodgkin’s lymphoma. Target Oncol. 2015;10(1):15–26. https://doi.org/10.1007/s11523-014-0324-y.
Kawashima H. Characteristics of Ibritumomab as radionuclide therapy agent. In: Hosono M, Chatal J-F, editors. Resistance to Ibritumomab in lymphoma. Cham: Springer International Publishing; 2018. p. 79–97.
Marcus R. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin’s lymphoma. Semin Oncol. 2005;32(1 Suppl 1):S36–43. https://doi.org/10.1053/j.seminoncol.2005.01.012.
Jacobs SA, Harrison AM, Swerdlow SH, Foon KA, Avril N, Vidnovic N, et al. Radioisotopic localization of 90Yttrium–Ibritumomab Tiuxetan in patients with CD20+ non-Hodgkin’s lymphoma. Mol Imaging Biol. 2009;11(1):39–45. https://doi.org/10.1007/s11307-008-0170-3.
Weber T, Bötticher B, Mier W, Sauter M, Krämer S, Leotta K, et al. High treatment efficacy by dual targeting of Burkitt’s lymphoma xenografted mice with a 177Lu-based CD22-specific radioimmunoconjugate and rituximab. Eur J Nucl Med Mol Imaging. 2016;43(3):489–98. https://doi.org/10.1007/s00259-015-3175-6.
Conti PS, White C, Pieslor P, Molina A, Aussie J, Foster P. The role of imaging with (111)in-ibritumomab tiuxetan in the ibritumomab tiuxetan (zevalin) regimen: results from a Zevalin imaging registry. J Nucl Med. 2005;46(11):1812–8.
MICAD Research Team. (111)In-Ibritumomab tiuxetan. Bethesda, MD: Molecular Imaging and Contrast Agent Database (MICAD); 2004.
Jacobs SA, Vidnovic N, Joyce J, McCook B, Torok F, Avril N. Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy. Clin Cancer Res. 2005;11(19 Pt 2):7146s–50s. https://doi.org/10.1158/1078-0432.CCR-1004-0003.
Theuer CP, Leigh BR, Multani PS, Allen RS, Liang BC. Radioimmunotherapy of non-Hodgkin's lymphoma: clinical development of the Zevalin regimen. Biotechnol Annu Rev. 2004;10:265–95. https://doi.org/10.1016/S1387-2656(04)10011-2.
Czuczman MS, Emmanouilides C, Darif M, Witzig TE, Gordon LI, Revell S, et al. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol. 2007;25(27):4285–92. https://doi.org/10.1200/JCO.2006.09.2882.
Iagaru A, Gambhir SS, Goris ML. 90Y-ibritumomab therapy in refractory non-Hodgkin's lymphoma: observations from 111In-ibritumomab pretreatment imaging. J Nucl Med. 2008;49(11):1809–12. https://doi.org/10.2967/jnumed.108.052928.
Morschhauser F, Radford J, Van Hoof A, Botto B, Rohatiner AZ, Salles G, et al. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the international, randomized, phase III first-LineIndolent trial. J Clin Oncol. 2013;31(16):1977–83. https://doi.org/10.1200/jco.2012.45.6400.
Wagner JY, Schwarz K, Schreiber S, Schmidt B, Wester HJ, Schwaiger M, et al. Myeloablative anti-CD20 radioimmunotherapy +/− high-dose chemotherapy followed by autologous stem cell support for relapsed/refractory B-cell lymphoma results in excellent long-term survival. Oncotarget. 2013, 4(6):899–910. https://doi.org/10.18632/oncotarget.1037.
Ali AM, Dehdashti F, DiPersio JF, Cashen AF. Radioimmunotherapy-based conditioning for hematopoietic stem cell transplantation: another step forward. Blood Rev. 2016;30(5):389–99. https://doi.org/10.1016/j.blre.2016.04.007.
Sutamtewagul G, Link BK. Novel treatment approaches and future perspectives in follicular lymphoma. Ther Adv Hematol. 2019;10:2040620718820510. https://doi.org/10.1177/2040620718820510.
Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20(15):3262–9. https://doi.org/10.1200/JCO.2002.11.017.
Eskian M, Khorasanizadeh M, Zinzani PL, Rezaei N. Radioimmunotherapy as the first line of treatment in non-Hodgkin lymphoma. Immunotherapy. 2018;10(8):699–711. https://doi.org/10.2217/imt-2017-0169.
Hohloch K, Windemuth-Kieselbach C, Kolz J, Zinzani PL, Cacchione R, Jurczak W, et al. Radioimmunotherapy (RIT) for follicular lymphoma achieves long term lymphoma control in first line and at relapse: 8-year follow-up data of 281 patients from the international RIT-registry. Br J Haematol. 2019;184(6):949–56. https://doi.org/10.1111/bjh.15712.
Michel RB, Rosario AV, Brechbiel MW, Jackson TJ, Goldenberg DM, Mattes MJ. Experimental therapy of disseminated B-cell lymphoma xenografts with 213Bi-labeled anti-CD74. Nucl Med Biol. 2003;30(7):715–23.
Park SI, Shenoi J, Pagel JM, Hamlin DK, Wilbur DS, Orgun N, et al. Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease. Blood. 2010;116(20):4231–9. https://doi.org/10.1182/blood-2010-05-282327.
Fanale MA, Younes A. Monoclonal antibodies in the treatment of non-Hodgkin’s lymphoma. Drugs. 2007;67(3):333–50. https://doi.org/10.2165/00003495-200767030-00002.
Ma D, McDevitt MR, Barendswaard E, Lai L, Curcio MJ, Pellegrini V, et al. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies. Leukemia. 2002;16(1):60–6. https://doi.org/10.1038/sj.leu.2402320.
Sullivan-Chang L, O’Donnell RT, Tuscano JM. Targeting CD22 in B-cell malignancies: current status and clinical outlook. BioDrugs. 2013;27(4):293–304. https://doi.org/10.1007/s40259-013-0016-7.
Sharkey RM, Karacay H, Goldenberg DM. Improving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclides. Cancer. 2010;116(4 Suppl):1134–45. https://doi.org/10.1002/cncr.24802.
Morschhauser F, Kraeber-Bodere F, Wegener WA, Harousseau JL, Petillon MO, Huglo D, et al. High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma. J Clin Oncol. 2010;28(23):3709–16. https://doi.org/10.1200/JCO.2009.27.7863.
Chevallier P, Eugene T, Robillard N, Isnard F, Nicolini F, Escoffre-Barbe M, et al. (90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study. Lancet Haematol. 2015;2(3):e108–17. https://doi.org/10.1016/S2352-3026(15)00020-4.
Witzig TE, Tomblyn MB, Misleh JG, Kio EA, Sharkey RM, Wegener WA, et al. Anti-CD22 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma. Haematologica. 2014;99(11):1738–45. https://doi.org/10.3324/haematol.2014.112110.
Bailly C, Bodet-Milin C, Guerard F, Chouin N, Gaschet J, Cherel M, et al. Radioimmunotherapy of lymphomas. In: Giovanella L, editor. Nuclear medicine therapy: side effects and complications. Cham: Springer International Publishing; 2019. p. 113–21.
Payandeh Z, Noori E, Khalesi B, Mard-Soltani M, Abdolalizadeh J, Khalili S. Anti-CD37 targeted immunotherapy of B-cell malignancies. Biotechnol Lett. 2018;40(11–12):1459–66. https://doi.org/10.1007/s10529-018-2612-6.
Kolstad A, Madsbu U, Beasley M, Bayne M, Illidge TM, O'Rourke N, et al. LYMRIT 37-01: a phase I/II study of 177Lu-Lilotomab Satetraxetan (Betalutin®) antibody-Radionuclide-Conjugate (ARC) for the treatment of relapsed non-Hodgkin's Lymphoma (NHL)—analysis with 6-month follow-up. Blood. 2018;132(Suppl. 1):2879. https://doi.org/10.1182/blood-2018-99-110555.
Gritti G, Gianatti A, Petronzelli F, De Santis R, Pavoni C, Rossi RL, et al. Evaluation of tenascin-C by tenatumomab in T-cell non-Hodgkin lymphomas identifies a new target for radioimmunotherapy. Oncotarget. 2018;9(11):9766–75. https://doi.org/10.18632/oncotarget.23919.
Aloj L, D'Ambrosio L, Aurilio M, Morisco A, Frigeri F, Caraco C, et al. Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging. 2014;41(5):867–77. https://doi.org/10.1007/s00259-013-2658-6.
Rizzieri DA, Akabani G, Zalutsky MR, Coleman RE, Metzler SD, Bowsher JE, et al. Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma. Blood. 2004;104(3):642–8. https://doi.org/10.1182/blood-2003-12-4264.
Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540–9. https://doi.org/10.1200/JCO.2014.56.2025.
Vallera DA, Elson M, Brechbiel MW, Dusenbery KE, Burns LJ, Jaszcz WB, et al. Radiotherapy of CD19 expressing Daudi tumors in nude mice with Yttrium-90-labeled anti-CD19 antibody. Cancer Biother Radiopharm. 2004;19(1):11–23. https://doi.org/10.1089/108497804773391630.
Burke JM, Jurcic JG. Radioimmunotherapy of leukemia. Adv Pharmacol. 2004;51:185–208. https://doi.org/10.1016/S1054-3589(04)51008-6.
De Propris MS, Raponi S, Diverio D, Milani ML, Meloni G, Falini B, et al. High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation. Haematologica. 2011;96(10):1548–51. https://doi.org/10.3324/haematol.2011.043786.
Walter RB. Investigational CD33-targeted therapeutics for acute myeloid leukemia. Expert Opin Investig Drugs. 2018;27(4):339–48. https://doi.org/10.1080/13543784.2018.1452911.
Garfin PM, Feldman EJ. Antibody-based treatment of acute myeloid leukemia. Curr Hematol Malig Rep. 2016;11(6):545–52. https://doi.org/10.1007/s11899-016-0349-7.
Jiang Y, Xu P, Yao D, Chen X, Dai H. CD33, CD96 and Death Associated Protein Kinase (DAPK) expression are associated with the survival rate and/or response to the chemotherapy in the patients with Acute Myeloid Leukemia (AML). Med Sci Monit. 2017;23:1725–32. https://doi.org/10.12659/msm.900305.
Scheinberg DA, Lovett D, Divgi CR, Graham MC, Berman E, Pentlow K, et al. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J Clin Oncol. 1991;9(3):478–90. https://doi.org/10.1200/JCO.1991.9.3.478.
Jurcic JG, Caron PC, Nikula TK, Papadopoulos EB, Finn RD, Gansow OA, et al. Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias. Cancer Res. 1995;55(23 Suppl):5908s–10s.
Burke JM, Caron PC, Papadopoulos EB, Divgi CR, Sgouros G, Panageas KS, et al. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. Bone Marrow Transplant. 2003;32(6):549–56. https://doi.org/10.1038/sj.bmt.1704201.
Burke JM, Jurcic JG, Scheinberg DA. Radioimmunotherapy for acute leukemia. Cancer Control: J Moffitt Cancer Center. 2002;9(2):106–13. https://doi.org/10.1177/107327480200900203.
Kozempel J, Mokhodoeva O, Vlk M. Progress in targeted Alpha-particle therapy. What we learned about recoils release from in vivo generators. Molecules. 2018;23(3) https://doi.org/10.3390/molecules23030581.
Atallah E, Berger M, Jurcic J, Roboz G, Tse W, Mawad R, et al. A phase 2 study of Actinium-225 (225Ac)-lintuzumab in older patients with untreated acute myeloid leukemia (AML). J Med Imaging Radiat Sci. 2019;50(1):S37. https://doi.org/10.1016/j.jmir.2019.03.113.
Ehninger A, Kramer M, Rollig C, Thiede C, Bornhauser M, von Bonin M, et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer J. 2014;4:e218. https://doi.org/10.1038/bcj.2014.39.
Jilani I, Estey E, Huh Y, Joe Y, Manshouri T, Yared M, et al. Differences in CD33 intensity between various myeloid neoplasms. Am J Clin Pathol. 2002;118(4):560–6. https://doi.org/10.1309/1WMW-CMXX-4WN4-T55U.
Saint-Paul L, Nguyen CH, Buffiere A, Pais de Barros JP, Hammann A, Landras-Guetta C, et al. CD45 phosphatase is crucial for human and murine acute myeloid leukemia maintenance through its localization in lipid rafts. Oncotarget. 2016;7(40):64785–97. https://doi.org/10.18632/oncotarget.11622.
Matthews DC, Appelbaum FR, Eary JF, Fisher DR, Durack LD, Hui TE, et al. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood. 1999;94(4):1237–47.
Matthews DC, Appelbaum FR, Eary JF, Fisher DR, Durack LD, Bush SA, et al. Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood. 1995;85(4):1122–31.
Pagel JM, Appelbaum FR, Eary JF, Rajendran J, Fisher DR, Gooley T, et al. 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood. 2006;107(5):2184–91. https://doi.org/10.1182/blood-2005-06-2317.
Nakamae H, Wilbur DS, Hamlin DK, Thakar MS, Santos EB, Fisher DR, et al. Biodistributions, myelosuppression, and toxicities in mice treated with an anti-CD45 antibody labeled with the alpha-emitting radionuclides bismuth-213 or astatine-211. Cancer Res. 2009;69(6):2408–15. https://doi.org/10.1158/0008-5472.CAN-08-4363.
Chen Y, Kornblit B, Hamlin DK, Sale GE, Santos EB, Wilbur DS, et al. Durable donor engraftment after radioimmunotherapy using alpha-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation. Blood. 2012;119(5):1130–8. https://doi.org/10.1182/blood-2011-09-380436.
Morsink LM, Walter RB. Novel monoclonal antibody-based therapies for acute myeloid leukemia. Best Pract Res Clin Haematol. 2019;32(2):116–26. https://doi.org/10.1016/j.beha.2019.05.002.
Williams BA, Law A, Hunyadkurti J, Desilets S, Leyton JV, Keating A. Antibody therapies for acute myeloid leukemia: unconjugated, toxin-conjugated, radio-conjugated and multivalent formats. J Clin Med. 2019;8(8):1261. https://doi.org/10.3390/jcm8081261.
Yabushita T, Satake H, Maruoka H, Morita M, Katoh D, Shimomura Y, et al. Expression of multiple leukemic stem cell markers is associated with poor prognosis in de novo acute myeloid leukemia. Leuk Lymphoma. 2018;59(9):2144–51. https://doi.org/10.1080/10428194.2017.1410888.
Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med. 2006;12(10):1167–74. https://doi.org/10.1038/nm1483.
Leyton JV, Gao C, Williams B, Keating A, Minden M, Reilly RM. A radiolabeled antibody targeting CD123(+) leukemia stem cells - initial radioimmunotherapy studies in NOD/SCID mice engrafted with primary human AML. Leukemia Res Rep. 2015;4(2):55–9. https://doi.org/10.1016/j.lrr.2015.07.003.
Leyton JV, Williams B, Gao C, Keating A, Minden M, Reilly RM. MicroSPECT/CT imaging of primary human AML engrafted into the bone marrow and spleen of NOD/SCID mice using 111In-DTPA-NLS-CSL360 radioimmunoconjugates recognizing the CD123+/CD131- epitope expressed by leukemia stem cells. Leuk Res. 2014;38(11):1367–73. https://doi.org/10.1016/j.leukres.2014.09.005.
Leyton JV, Hu M, Gao C, Turner PV, Dick JE, Minden M, et al. Auger electron radioimmunotherapeutic agent specific for the CD123+/CD131− phenotype of the leukemia stem cell population. J Nucl Med. 2011;52(9):1465–73. https://doi.org/10.2967/jnumed.111.087668.
Steiner M, Neri D. Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends. Clin Cancer Res. 2011;17(20):6406–16. https://doi.org/10.1158/1078-0432.CCR-11-0483.
Baxter LT, Jain RK. Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. Microvasc Res. 1989;37(1):77–104.
Boucher Y, Baxter LT, Jain RK. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res. 1990;50(15):4478–84.
Jain RK. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res. 1990;50(3 Suppl):814s–9s.
Prasad V, Baum RP, Oliva JP. Radioimmunotherapy. In: Ahmadzadehfar H, Biersack H-J, Freeman LM, Zuckier LS, editors. Clinical nuclear medicine. Cham: Springer International Publishing; 2020. p. 917–49.
Lau J, Lin KS, Bénard F. Past, present, and future: development of Theranostic agents targeting carbonic anhydrase IX. Theranostics. 2017;7(17):4322–39. https://doi.org/10.7150/thno.21848.
Scott AM, Wiseman G, Welt S, Adjei A, Lee FT, Hopkins W, et al. A phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res. 2003;9(5):1639–47.
Klein M, Lotem M, Peretz T, Zwas ST, Mizrachi S, Liberman Y, et al. Safety and efficacy of 188-rhenium-labeled antibody to melanin in patients with metastatic melanoma. J Skin Cancer. 2013;2013:828329. https://doi.org/10.1155/2013/828329.
Diamandis EP, Bast RC Jr, Gold P, Chu TM, Magnani JL. Reflection on the discovery of carcinoembryonic antigen, prostate-specific antigen, and cancer antigens CA125 and CA19-9. Clin Chem. 2013;59(1):22–31. https://doi.org/10.1373/clinchem.2012.187047.
Campos-da-Paz M, Dorea JG, Galdino AS, Lacava ZGM. de Fatima Menezes Almeida Santos M. carcinoembryonic antigen (CEA) and hepatic metastasis in colorectal cancer: update on biomarker for clinical and biotechnological approaches. Recent Pat Biotechnol. 2018;12(4):269–79. https://doi.org/10.2174/1872208312666180731104244.
Koppe MJ, Bleichrodt RP, Oyen WJ, Boerman OC. Radioimmunotherapy and colorectal cancer. Br J Surg. 2005;92(3):264–76. https://doi.org/10.1002/bjs.4936.
Bertagnolli MM. Radioimmunotherapy for colorectal cancer. Clin Cancer Res. 2005;11(13):4637–8. https://doi.org/10.1158/1078-0432.CCR-05-0485.
Sahlmann CO, Homayounfar K, Niessner M, Dyczkowski J, Conradi LC, Braulke F, et al. Repeated adjuvant anti-CEA radioimmunotherapy after resection of colorectal liver metastases: safety, feasibility, and long-term efficacy results of a prospective phase 2 study. Cancer. 2017;123(4):638–49. https://doi.org/10.1002/cncr.30390.
Liersch T, Meller J, Bittrich M, Kulle B, Becker H, Goldenberg DM. Update of carcinoembryonic antigen radioimmunotherapy with (131)I-labetuzumab after salvage resection of colorectal liver metastases: comparison of outcome to a contemporaneous control group. Ann Surg Oncol. 2007;14(9):2577–90. https://doi.org/10.1245/s10434-006-9328-x.
Wong JY, Shibata S, Williams LE, Kwok CS, Liu A, Chu DZ, et al. A phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer. Clin Cancer Res. 2003;9(16 Pt 1):5842–52.
Hanaoka H, Kuroki M, Yamaguchi A, Achmad A, Iida Y, Higuchi T, et al. Fractionated radioimmunotherapy with 90Y-labeled fully human anti-CEA antibody. Cancer Biother Radiopharm. 2014;29(2):70–6. https://doi.org/10.1089/cbr.2013.1562.
Cahan B, Leong L, Wagman L, Yamauchi D, Shibata S, Wilzcynski S, et al. Phase I/II trial of anticarcinoembryonic antigen radioimmunotherapy, gemcitabine, and hepatic arterial infusion of fluorodeoxyuridine postresection of liver metastasis for colorectal carcinoma. Cancer Biother Radiopharm. 2017;32(7):258–65.
Tagawa ST, Beltran H, Vallabhajosula S, Goldsmith SJ, Osborne J, Matulich D, et al. Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer. 2010;116(4 Suppl):1075–83. https://doi.org/10.1002/cncr.24795.
Kuo HT, Merkens H, Zhang Z, Uribe CF, Lau J, Zhang C, et al. Enhancing treatment efficacy of (177)Lu-PSMA-617 with the conjugation of an albumin-binding motif: preclinical dosimetry and Endoradiotherapy studies. Mol Pharm. 2018;15(11):5183–91. https://doi.org/10.1021/acs.molpharmaceut.8b00720.
Vallabhajosula S, Goldsmith SJ, Kostakoglu L, Milowsky MI, Nanus DM, Bander NH. Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity. Clin Cancer Res. 2005;11(19 Pt 2):7195s–200s. https://doi.org/10.1158/1078-0432.CCR-1004-0023.
Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH. Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol. 2004;22(13):2522–31. https://doi.org/10.1200/JCO.2004.09.154.
Tagawa ST, Akhtar NH, Nikolopoulou A, Kaur G, Robinson B, Kahn R, et al. Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody j591 in men with metastatic castration-resistant prostate cancer. Front Oncol. 2013;3:214. https://doi.org/10.3389/fonc.2013.00214.
Tagawa ST, Vallabhajosula S, Christos PJ, Jhanwar YS, Batra JS, Lam L, et al. Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 ((177) Lu-J591) for metastatic castration-resistant prostate cancer. Cancer. 2019;125(15):2561–9. https://doi.org/10.1002/cncr.32072.
Scheinberg DA, McDevitt MR. Actinium-225 in targeted alpha-particle therapeutic applications. Curr Radiopharm. 2011;4(4):306–20.
Tagawa ST, Vallabhajosula S, Jhanwar Y, Ballman KV, Hackett A, Emmerich L, et al. Phase I dose-escalation study of 225Ac-J591 for progressive metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol. 2018;36(6 Suppl):TPS399. https://doi.org/10.1200/JCO.2018.36.6_suppl.TPS399.
Milenic DE, Baidoo KE, Kim YS, Barkley R, Brechbiel MW. Targeted alpha-particle radiation therapy of HER1-positive disseminated intraperitoneal disease: An investigation of the human anti-EGFR monoclonal antibody. Panitumumab Transl Oncol. 2017;10(4):535–45. https://doi.org/10.1016/j.tranon.2017.04.004.
Melzig C, Golestaneh AF, Mier W, Schwager C, Das S, Schlegel J, et al. Combined external beam radiotherapy with carbon ions and tumor targeting endoradiotherapy. Oncotarget. 2018;9(52):29985–30004. https://doi.org/10.18632/oncotarget.25695.
Kim EJ, Kim BS, Choi DB, Chi SG, Choi TH. Enhanced tumor retention of radioiodinated anti-epidermal growth factor receptor antibody using novel bifunctional iodination linker for radioimmunotherapy. Oncol Rep. 2016;35(6):3159–68. https://doi.org/10.3892/or.2016.4706.
Milenic DE, Baidoo KE, Kim YS, Brechbiel MW. Evaluation of cetuximab as a candidate for targeted alpha-particle radiation therapy of HER1-positive disseminated intraperitoneal disease. mAbs. 2015;7(1):255–64. https://doi.org/10.4161/19420862.2014.985160.
Song IH, Lee TS, Park YS, Lee JS, Lee BC, Moon BS, et al. Immuno-PET imaging and Radioimmunotherapy of 64Cu-/177Lu-labeled anti-EGFR antibody in esophageal squamous cell carcinoma model. J Nucl Med. 2016;57(7):1105–11. https://doi.org/10.2967/jnumed.115.167155.
Fazel J, Rotzer S, Seidl C, Feuerecker B, Autenrieth M, Weirich G, et al. Fractionated intravesical radioimmunotherapy with (213)bi-anti-EGFR-MAb is effective without toxic side-effects in a nude mouse model of advanced human bladder carcinoma. Cancer Biol Ther. 2015;16(10):1526–34. https://doi.org/10.1080/15384047.2015.1071735.
Chang YJ, Ho CL, Cheng KH, Kuo WI, Lee WC, Lan KL, et al. Biodistribution, pharmacokinetics and radioimmunotherapy of (188)re-cetuximab in NCI-H292 human lung tumor-bearing nude mice. Investig New Drugs. 2019; https://doi.org/10.1007/s10637-018-00718-8.
Luo TY, Cheng PC, Chiang PF, Chuang TW, Yeh CH, Lin WJ. 188Re-HYNIC-trastuzumab enhances the effect of apoptosis induced by trastuzumab in HER2-overexpressing breast cancer cells. Ann Nucl Med. 2015;29(1):52–62. https://doi.org/10.1007/s12149-014-0908-8.
Li HK, Morokoshi Y, Nagatsu K, Kamada T, Hasegawa S. Locoregional therapy with alpha-emitting trastuzumab against peritoneal metastasis of human epidermal growth factor receptor 2-positive gastric cancer in mice. Cancer Sci. 2017;108(8):1648–56. https://doi.org/10.1111/cas.13282.
Timmermand OV, Elgqvist J, Beattie KA, Orbom A, Larsson E, Eriksson SE, et al. Preclinical efficacy of hK2 targeted [(177)Lu]hu11B6 for prostate cancer theranostics. Theranostics. 2019;9(8):2129–42. https://doi.org/10.7150/thno.31179.
Timmermand OV, Nilsson J, Strand SE, Elgqvist J. High resolution digital autoradiographic and dosimetric analysis of heterogeneous radioactivity distribution in xenografted prostate tumors. Med Phys. 2016;43(12):6632. https://doi.org/10.1118/1.4967877.
Vilhelmsson Timmermand O, Larsson E, Ulmert D, Tran TA, Strand S. Radioimmunotherapy of prostate cancer targeting human kallikrein-related peptidase 2. EJNMMI Res. 2016;6(1):27. https://doi.org/10.1186/s13550-016-0181-z.
Thorek DLJ, Ku AT, Mitsiades N, Veach D, Watson PA, Metha D, et al. Harnessing androgen receptor pathway activation for targeted alpha particle Radioimmunotherapy of breast cancer. Clin Cancer Res. 2019;25(2):881–91. https://doi.org/10.1158/1078-0432.CCR-18-1521.
Allen KJH, Jiao R, Malo ME, Frank C, Fisher DR, Rickles D, et al. Comparative radioimmunotherapy of experimental melanoma with novel humanized antibody to melanin labeled with 213Bismuth and 177Lutetium. Pharmaceutics. 2019;11(7) https://doi.org/10.3390/pharmaceutics11070348.
Kasten BB, Arend RC, Katre AA, Kim H, Fan J, Ferrone S, et al. B7-H3-targeted (212)Pb radioimmunotherapy of ovarian cancer in preclinical models. Nucl Med Biol. 2017;47:23–30. https://doi.org/10.1016/j.nucmedbio.2017.01.003.
Kasten BB, Gangrade A, Kim H, Fan J, Ferrone S, Ferrone CR, et al. (212)Pb-labeled B7-H3-targeting antibody for pancreatic cancer therapy in mouse models. Nucl Med Biol. 2018;58:67–73. https://doi.org/10.1016/j.nucmedbio.2017.12.004.
Lindenblatt D, Terraneo N, Pellegrini G, Cohrs S, Spycher PR, Vukovic D, et al. Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma. BMC Cancer. 2018;18(1):922. https://doi.org/10.1186/s12885-018-4836-1.
Basaco T, Pektor S, Bermudez JM, Meneses N, Heller M, Galvan JA, et al. Evaluation of radiolabeled girentuximab in vitro and in vivo. Pharmaceuticals (Basel). 2018;11(4) https://doi.org/10.3390/ph11040132.
Westrom S, Bonsdorff TB, Abbas N, Bruland OS, Jonasdottir TJ, Maelandsmo GM, et al. Evaluation of CD146 as target for Radioimmunotherapy against osteosarcoma. PLoS One. 2016;11(10):e0165382. https://doi.org/10.1371/journal.pone.0165382.
Fujiwara K, Koyama K, Suga K, Ikemura M, Saito Y, Hino A, et al. 90Y-labeled anti-ROBO1 monoclonal antibody exhibits antitumor activity against small cell lung cancer xenografts. PLoS One. 2015;10(5):e0125468. https://doi.org/10.1371/journal.pone.0125468.
Sugyo A, Tsuji AB, Sudo H, Okada M, Koizumi M, Satoh H, et al. Evaluation of efficacy of Radioimmunotherapy with 90Y-labeled fully human anti-transferrin receptor monoclonal antibody in pancreatic cancer mouse models. PLoS One. 2015;10(4):e0123761. https://doi.org/10.1371/journal.pone.0123761.
Derrien A, Gouard S, Maurel C, Gaugler MH, Bruchertseifer F, Morgenstern A, et al. Therapeutic efficacy of alpha-RIT using a (213)bi-anti-hCD138 antibody in a mouse model of ovarian peritoneal Carcinomatosis. Front Med. 2015;2:88. https://doi.org/10.3389/fmed.2015.00088.
Weng D, Jin X, Qin S, Lan X, Chen C, Sun X, et al. Radioimmunotherapy for CD133(+) colonic cancer stem cells inhibits tumor development in nude mice. Oncotarget. 2017;8(27):44004–14. https://doi.org/10.18632/oncotarget.16868.
Lang J, Lan X, Liu Y, Jin X, Wu T, Sun X, et al. Targeting cancer stem cells with an 131I-labeled anti-AC133 monoclonal antibody in human colorectal cancer xenografts. Nucl Med Biol. 2015;42(5):505–12. https://doi.org/10.1016/j.nucmedbio.2015.01.003.
Deshayes E, Ladjohounlou R, Le Fur P, Pichard A, Lozza C, Boudousq V, et al. Radiolabeled antibodies against Mullerian-inhibiting substance receptor, type II: new tools for a theranostic approach in ovarian cancer. J Nucl Med. 2018;59(8):1234–42. https://doi.org/10.2967/jnumed.118.208611.
Sugyo A, Tsuji AB, Sudo H, Koizumi M, Ukai Y, Kurosawa G, et al. Efficacy evaluation of combination treatment using gemcitabine and radioimmunotherapy with (90)Y-labeled fully human anti-CD147 monoclonal antibody 059-053 in a BxPC-3 xenograft mouse model of refractory pancreatic cancer. Int J Mol Sci. 2018;19(10) https://doi.org/10.3390/ijms19102979.
Li HK, Sugyo A, Tsuji AB, Morokoshi Y, Minegishi K, Nagatsu K, et al. Alpha-particle therapy for synovial sarcoma in the mouse using an astatine-211-labeled antibody against frizzled homolog 10. Cancer Sci. 2018;109(7):2302–9. https://doi.org/10.1111/cas.13636.
Ma S. Biology and clinical implications of CD133(+) liver cancer stem cells. Exp Cell Res. 2013;319(2):126–32. https://doi.org/10.1016/j.yexcr.2012.09.007.
Wei W, Jiang D, Ehlerding EB, Barnhart TE, Yang Y, Engle JW, et al. CD146-targeted multimodal image-guided Photoimmunotherapy of melanoma. Adv Sci (Weinh). 2019;6(9):1801237. https://doi.org/10.1002/advs.201801237.
Valkenburg KC, de Groot AE, Pienta KJ. Targeting the tumour stroma to improve cancer therapy. Nat Rev Clin Oncol. 2018;15(6):366–81. https://doi.org/10.1038/s41571-018-0007-1.
Welt S, Divgi CR, Scott AM, Garin-Chesa P, Finn RD, Graham M, et al. Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. J Clin Oncol. 1994;12(6):1193–203. https://doi.org/10.1200/JCO.1994.12.6.1193.
Fischer E, Chaitanya K, Wuest T, Wadle A, Scott AM, van den Broek M, et al. Radioimmunotherapy of fibroblast activation protein positive tumors by rapidly internalizing antibodies. Clin Cancer Res. 2012;18(22):6208–18. https://doi.org/10.1158/1078-0432.CCR-12-0644.
Guillermina F-F, Blanca O-G, Myrna Luna G, Clara Santos C, Nallely J-M, Erika A-V, et al. Radiolabeled protein-inhibitor peptides with rapid clinical translation towards imaging and therapy. Curr Med Chem. 2020;27:1–15. https://doi.org/10.2174/0929867327666191223121211.
Schliemann C, Neri D. Antibody-based vascular tumor targeting. Recent results in cancer research. Fortschritte der Krebsforschung Progres dans les recherches sur le cancer. 2010;180:201–16. https://doi.org/10.1007/978-3-540-78281-0_12.
Lee SY, Hong YD, Pyun MS, Felipe PM, Choi SJ. Radiolabeling of monoclonal anti-vascular endothelial growth factor receptor 1 (VEGFR 1) with (177)Lu for potential use in radioimmunotherapy. Appl Radiat Isot. 2009;67(7-8):1185–9. https://doi.org/10.1016/j.apradiso.2009.02.006.
Ebbinghaus C, Scheuermann J, Neri D, Elia G. Diagnostic and therapeutic applications of recombinant antibodies: targeting the extra-domain B of fibronectin, a marker of tumor angiogenesis. Curr Pharm Des. 2004;10(13):1537–49. https://doi.org/10.2174/1381612043384808.
Tijink BM, Neri D, Leemans CR, Budde M, Dinkelborg LM, Stigter-van Walsum M, et al. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med. 2006;47(7):1127–35.
El-Emir E, Dearling JL, Huhalov A, Robson MP, Boxer G, Neri D, et al. Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour models. Br J Cancer. 2007;96(12):1862–70. https://doi.org/10.1038/sj.bjc.6603806.
Spaeth N, Wyss MT, Pahnke J, Biollaz G, Trachsel E, Drandarov K, et al. Radioimmunotherapy targeting the extra domain B of fibronectin in C6 rat gliomas: a preliminary study about the therapeutic efficacy of iodine-131-labeled SIP(L19). Nucl Med Biol. 2006;33(5):661–6. https://doi.org/10.1016/j.nucmedbio.2006.05.001.
Dallas NA, Samuel S, Xia L, Fan F, Gray MJ, Lim SJ, et al. Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res. 2008;14(7):1931–7. https://doi.org/10.1158/1078-0432.CCR-07-4478.
Ehlerding EB, Lacognata S, Jiang D, Ferreira CA, Goel S, Hernandez R, et al. Targeting angiogenesis for radioimmunotherapy with a (177)Lu-labeled antibody. Eur J Nucl Med Mol Imaging. 2018;45(1):123–31. https://doi.org/10.1007/s00259-017-3793-2.
Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer. 2013;13(12):871–82. https://doi.org/10.1038/nrc3627.
Liu F, Qi L, Liu B, Liu J, Zhang H, Che D, et al. Fibroblast activation protein overexpression and clinical implications in solid tumors: a meta-analysis. PLoS One. 2015;10(3):e0116683. https://doi.org/10.1371/journal.pone.0116683.
Aung W, Tsuji AB, Sudo H, Sugyo A, Ukai Y, Kouda K, et al. Radioimmunotherapy of pancreatic cancer xenografts in nude mice using 90Y-labeled anti-alpha6beta4 integrin antibody. Oncotarget. 2016;7(25):38835–44. https://doi.org/10.18632/oncotarget.9631.
Veeravagu A, Liu Z, Niu G, Chen K, Jia B, Cai W, et al. Integrin αvβ3-targeted Radioimmunotherapy of glioblastoma Multiforme. Clin Cancer Res. 2008;14(22):7330–9. https://doi.org/10.1158/1078-0432.Ccr-08-0797.
Riva P, Franceschi G, Riva N, Casi M, Santimaria M, Adamo M. Role of nuclear medicine in the treatment of malignant gliomas: the locoregional radioimmunotherapy approach. Eur J Nucl Med. 2000;27(5):601–9. https://doi.org/10.1007/s002590050549.
Reardon DA, Zalutsky MR, Bigner DD. Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients. Expert Rev Anticancer Ther. 2007;7(5):675–87. https://doi.org/10.1586/14737140.7.5.675.
Raghavan R, Howell RW, Zalutsky MR. A model for optimizing delivery of targeted radionuclide therapies into resection cavity margins for the treatment of primary brain cancers. Biomed Phys Eng Express. 2017;3(3) https://doi.org/10.1088/2057-1976/aa6db9.
Aarts F, Bleichrodt RP, Oyen WJ, Boerman OC. Intracavitary radioimmunotherapy to treat solid tumors. Cancer Biother Radiopharm. 2008;23(1):92–107. https://doi.org/10.1089/cbr.2007.0412.
Huber R, Seidl C, Schmid E, Seidenschwang S, Becker KF, Schuhmacher C, et al. Locoregional alpha-radioimmunotherapy of intraperitoneal tumor cell dissemination using a tumor-specific monoclonal antibody. Clin Cancer Res. 2003;9(10 Pt 2):3922S–8S.
Kinuya S, Yokoyama K, Kawashima A, Hiramatsu T, Konishi S, Shuke N, et al. Pharmacologic intervention with angiotensin II and kininase inhibitor enhanced efficacy of radioimmunotherapy in human colon cancer xenografts. J Nucl Med. 2000;41(7):1244–9.
Chen A. PARP inhibitors: its role in treatment of cancer. Chin J Cancer. 2011;30(7):463–71. https://doi.org/10.5732/cjc.011.10111.
Gill MR, Falzone N, Du Y, Vallis KA. Targeted radionuclide therapy in combined-modality regimens. Lancet Oncol. 2017;18(7):e414–e23. https://doi.org/10.1016/S1470-2045(17)30379-0.
Al-Ejeh F, Shi W, Miranda M, Simpson PT, Vargas AC, Song S, et al. Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor. J Nucl Med. 2013;54(6):913–21. https://doi.org/10.2967/jnumed.112.111534.
Repetto-Llamazares AHV, Malenge MM, O'Shea A, Eiriksdottir B, Stokke T, Larsen RH, et al. Combination of (177) Lu-lilotomab with rituximab significantly improves the therapeutic outcome in preclinical models of non-Hodgkin's lymphoma. Eur J Haematol. 2018;101(4):522–31. https://doi.org/10.1111/ejh.13139.
Blumenthal RD, Kashi R, Stephens R, Sharkey RM, Goldenberg DM. Improved radioimmunotherapy of colorectal cancer xenografts using antibody mixtures against carcinoembryonic antigen and colon-specific antigen-p. Cancer Immunol Immunother. 1991;32(5):303–10. https://doi.org/10.1007/bf01789048.
Milenic DE, Brady ED, Garmestani K, Albert PS, Abdulla A, Brechbiel MW. Improved efficacy of alpha-particle-targeted radiation therapy: dual targeting of human epidermal growth factor receptor-2 and tumor-associated glycoprotein 72. Cancer. 2010;116(4 Suppl):1059–66. https://doi.org/10.1002/cncr.24793.
Pagel JM, Pantelias A, Hedin N, Wilbur S, Saganic L, Lin Y, et al. Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas. Cancer Res. 2007;67(12):5921–8. https://doi.org/10.1158/0008-5472.CAN-07-0080.
Deutsch E, Chargari C, Galluzzi L, Kroemer G. Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy. Lancet Oncol. 2019;20(8):e452–e63. https://doi.org/10.1016/S1470-2045(19)30171-8.
Levy A, Nigro G, Sansonetti PJ, Deutsch E. Candidate immune biomarkers for radioimmunotherapy. Biochim Biophys Acta Rev Cancer. 2017;1868(1):58–68. https://doi.org/10.1016/j.bbcan.2017.02.006.
Heery CR, Madan RA, Stein MN, Stadler WM, Di Paola RS, Rauckhorst M, et al. Samarium-153-EDTMP (Quadramet(R)) with or without vaccine in metastatic castration-resistant prostate cancer: a randomized Phase 2 trial. Oncotarget. 2016;7(42):69014–23. https://doi.org/10.18632/oncotarget.10883.
Fu R, Carroll L, Yahioglu G, Aboagye EO, Miller PW. Antibody fragment and Affibody ImmunoPET imaging agents: Radiolabelling strategies and applications. ChemMedChem. 2018;13(23):2466–78. https://doi.org/10.1002/cmdc.201800624.
Xenaki KT, Oliveira S, van Bergen En Henegouwen PMP. Antibody or antibody fragments: implications for molecular imaging and targeted therapy of solid tumors. Front Immunol. 2017;8:1287. https://doi.org/10.3389/fimmu.2017.01287.
Elgqvist J, Andersson H, Bernhardt P, Back T, Claesson I, Hultborn R, et al. Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab')2. Int J Radiat Oncol Biol Phys. 2006;66(4):1228–37. https://doi.org/10.1016/j.ijrobp.2006.07.003.
Back T, Chouin N, Lindegren S, Kahu H, Jensen H, Albertsson P, et al. Cure of human ovarian carcinoma solid xenografts by fractionated alpha-radioimmunotherapy with (211)at-MX35-F(ab')2: influence of absorbed tumor dose and effect on long-term survival. J Nucl Med. 2017;58(4):598–604. https://doi.org/10.2967/jnumed.116.178327.
Tolmachev V, Nilsson FY, Widstrom C, Andersson K, Rosik D, Gedda L, et al. 111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. J Nucl Med. 2006;47(5):846–53.
Tolmachev V, Orlova A, Pehrson R, Galli J, Baastrup B, Andersson K, et al. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res. 2007;67(6):2773–82. https://doi.org/10.1158/0008-5472.CAN-06-1630.
Wiehr S, Buhler P, Gierschner D, Wolf P, Rolle AM, Kesenheimer C, et al. Pharmacokinetics and PET imaging properties of two recombinant anti-PSMA antibody fragments in comparison to their parental antibody. Prostate. 2014;74(7):743–55. https://doi.org/10.1002/pros.22794.
Tavare R, McCracken MN, Zettlitz KA, Knowles SM, Salazar FB, Olafsen T, et al. Engineered antibody fragments for immuno-PET imaging of endogenous CD8+ T cells in vivo. Proc Natl Acad Sci U S A. 2014;111(3):1108–13. https://doi.org/10.1073/pnas.1316922111.
Lutje S, Franssen GM, Sharkey RM, Laverman P, Rossi EA, Goldenberg DM, et al. Anti-CEA antibody fragments labeled with [(18)F]AlF for PET imaging of CEA-expressing tumors. Bioconjug Chem. 2014;25(2):335–41. https://doi.org/10.1021/bc4004926.
Frejd FY, Kim KT. Affibody molecules as engineered protein drugs. Exp Mol Med. 2017;49(3):e306. https://doi.org/10.1038/emm.2017.35.
Goodwin DA, Meares CF, McTigue M, Chaovapong W, Diamanti CI, Ransone CH, et al. Pretargeted immunoscintigraphy: effect of hapten valency on murine tumor uptake. J Nucl Med. 1992;33(11):2006–13.
Bailly C, Bodet-Milin C, Rousseau C, Faivre-Chauvet A, Kraeber-Bodere F, Barbet J. Pretargeting for imaging and therapy in oncological nuclear medicine. EJNMMI Radiopharm Chem. 2017;2(1):6. https://doi.org/10.1186/s41181-017-0026-8.
Verhoeven M, Seimbille Y, Dalm SU. Therapeutic applications of pretargeting. Pharmaceutics. 2019;11(9) https://doi.org/10.3390/pharmaceutics11090434.
Liu G. A revisit to the Pretargeting concept-a target conversion. Front Pharmacol. 2018;9:1476. https://doi.org/10.3389/fphar.2018.01476.
Altai M, Membreno R, Cook B, Tolmachev V, Zeglis BM. Pretargeted imaging and therapy. J Nucl Med. 2017;58(10):1553–9. https://doi.org/10.2967/jnumed.117.189944.
Patra M, Zarschler K, Pietzsch HJ, Stephan H, Gasser G. New insights into the pretargeting approach to image and treat tumours. Chem Soc Rev. 2016;45(23):6415–31. https://doi.org/10.1039/c5cs00784d.
Steen EJL, Edem PE, Norregaard K, Jorgensen JT, Shalgunov V, Kjaer A, et al. Pretargeting in nuclear imaging and radionuclide therapy: improving efficacy of theranostics and nanomedicines. Biomaterials. 2018;179:209–45. https://doi.org/10.1016/j.biomaterials.2018.06.021.
Knight JC, Cornelissen B. Bioorthogonal chemistry: implications for pretargeted nuclear (PET/SPECT) imaging and therapy. Am J Nucl Med Mol Imaging. 2014;4(2):96–113.
Paganelli G, Chinol M, Maggiolo M, Sidoli A, Corti A, Baroni S, et al. The three-step pretargeting approach reduces the human anti-mouse antibody response in patients submitted to radioimmunoscintigraphy and radioimmunotherapy. Eur J Nucl Med. 1997;24(3):350–1. https://doi.org/10.1007/bf01728778.
Paganelli G, Magnani P, Zito F, Villa E, Sudati F, Lopalco L, et al. Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res. 1991;51(21):5960–6.
Paganelli G, Malcovati M, Fazio F. Monoclonal antibody pretargetting techniques for tumour localization: the avidin-biotin system. International workshop on techniques for amplification of tumour targetting. Nucl Med Commun. 1991;12(3):211–34. https://doi.org/10.1097/00006231-199103000-00006.
Weiden PL, Breitz HB, Press O, Appelbaum JW, Bryan JK, Gaffigan S, et al. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results. Cancer Biother Radiopharm. 2000;15(1):15–29. https://doi.org/10.1089/cbr.2000.15.15.
Domingo RJ, Reilly RM. Pre-targeted radioimmunotherapy of human colon cancer xenografts in athymic mice using streptavidin-CC49 monoclonal antibody and 90Y-DOTA-biotin. Nucl Med Commun. 2000;21(1):89–96. https://doi.org/10.1097/00006231-200001000-00015.
Frost SH, Back T, Chouin N, Hultborn R, Jacobsson L, Elgqvist J, et al. Comparison of 211At-PRIT and 211At-RIT of ovarian microtumors in a nude mouse model. Cancer Biother Radiopharm. 2013;28(2):108–14. https://doi.org/10.1089/cbr.2012.1281.
Kontermann RE, Brinkmann U. Bispecific antibodies. Drug Discov Today. 2015;20(7):838–47. https://doi.org/10.1016/j.drudis.2015.02.008.
Le Doussal JM, Martin M, Gautherot E, Delaage M, Barbet J. In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. J Nucl Med. 1989;30(8):1358–66.
Cheal SM, Fung EK, Patel M, Xu H, Guo HF, Zanzonico PB, et al. Curative multicycle radioimmunotherapy monitored by quantitative SPECT/CT-based theranostics, using bispecific antibody pretargeting strategy in colorectal cancer. J Nucl Med. 2017;58(11):1735–42. https://doi.org/10.2967/jnumed.117.193250.
Chang CH, Sharkey RM, Rossi EA, Karacay H, McBride W, Hansen HJ, et al. Molecular advances in pretargeting radioimunotherapy with bispecific antibodies. Mol Cancer Ther. 2002;1(7):553–63.
Gruaz-Guyon A, Janevik-Ivanovska E, Raguin O, De Labriolle-Vaylet C, Barbet J. Radiolabeled bivalent haptens for tumor immunodetection and radioimmunotherapy. Q J Nucl Med. 2001;45(2):201–6.
Green DJ, Frayo SL, Lin Y, Hamlin DK, Fisher DR, Frost SH, et al. Comparative analysis of bispecific antibody and streptavidin-targeted radioimmunotherapy for B-cell cancers. Cancer Res. 2016;76(22):6669–79. https://doi.org/10.1158/0008-5472.CAN-16-0571.
Green DJ, O'Steen S, Lin Y, Comstock ML, Kenoyer AL, Hamlin DK, et al. CD38-bispecific antibody pretargeted radioimmunotherapy for multiple myeloma and other B-cell malignancies. Blood. 2018;131(6):611–20. https://doi.org/10.1182/blood-2017-09-807610.
van Rij CM, Frielink C, Goldenberg DM, Sharkey RM, Lutje S, McBride WJ, et al. Pretargeted radioimmunotherapy of prostate cancer with an anti-TROP-2xAnti-HSG bispecific antibody and a (177)Lu-labeled peptide. Cancer Biother Radiopharm. 2014;29(8):323–9. https://doi.org/10.1089/cbr.2014.1660.
van Rij CM, Lutje S, Frielink C, Sharkey RM, Goldenberg DM, Franssen GM, et al. Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody. Eur J Nucl Med Mol Imaging. 2013;40(9):1377–83. https://doi.org/10.1007/s00259-013-2434-7.
Schoffelen R, Boerman OC, Goldenberg DM, Sharkey RM, van Herpen CM, Franssen GM, et al. Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results. Br J Cancer. 2013;109(4):934–42. https://doi.org/10.1038/bjc.2013.376.
Bodet-Milin C, Bailly C, Touchefeu Y, Frampas E, Bourgeois M, Rauscher A, et al. Clinical results in medullary thyroid carcinoma suggest high potential of Pretargeted Immuno-PET for tumor imaging and Theranostic approaches. Front Med. 2019;6:124. https://doi.org/10.3389/fmed.2019.00124.
Cheal SM, Xu H, Guo H-F, Patel M, Punzalan B, Fung EK, et al. Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: curative treatment of HER2-positive breast carcinoma. Theranostics. 2018;8(18):5106–25. https://doi.org/10.7150/thno.26585.
Zeglis BM, Brand C, Abdel-Atti D, Carnazza KE, Cook BE, Carlin S, et al. Optimization of a pretargeted strategy for the PET imaging of colorectal carcinoma via the modulation of radioligand pharmacokinetics. Mol Pharm. 2015;12(10):3575–87. https://doi.org/10.1021/acs.molpharmaceut.5b00294.
Membreno R, Cook BE, Fung K, Lewis JS, Zeglis BM. Click-mediated pretargeted radioimmunotherapy of colorectal carcinoma. Mol Pharm. 2018;15(4):1729–34. https://doi.org/10.1021/acs.molpharmaceut.8b00093.
Kuijpers WH, Bos ES, Kaspersen FM, Veeneman GH, van Boeckel CA. Specific recognition of antibody-oligonucleotide conjugates by radiolabeled antisense nucleotides: a novel approach for two-step radioimmunotherapy of cancer. Bioconjug Chem. 1993;4(1):94–102. https://doi.org/10.1021/bc00019a013.
Liu G, Mang'era K, Liu N, Gupta S, Rusckowski M, Hnatowich DJ. Tumor pretargeting in mice using (99m)Tc-labeled morpholino, a DNA analog. J Nucl Med. 2002;43(3):384–91.
Liu G, Dou S, Baker S, Akalin A, Cheng D, Chen L, et al. A preclinical 188Re tumor therapeutic investigation using MORF/cMORF pretargeting and an antiTAG-72 antibody CC49. Cancer Biol Ther. 2010;10(8):767–74. https://doi.org/10.4161/cbt.10.8.12879.
Houghton JL, Membreno R, Abdel-Atti D, Cunanan KM, Carlin S, Scholz WW, et al. Establishment of the in vivo efficacy of pretargeted radioimmunotherapy utilizing inverse electron demand Diels-Alder click chemistry. Mol Cancer Ther. 2017;16(1):124–33. https://doi.org/10.1158/1535-7163.Mct-16-0503.
Poty S, Carter LM, Mandleywala K, Membreno R, Abdel-Atti D, Ragupathi A, et al. Leveraging bioorthogonal click chemistry to improve (225)Ac-radioimmunotherapy of pancreatic ductal adenocarcinoma. Clin Cancer Res. 2019;25(2):868–80. https://doi.org/10.1158/1078-0432.CCR-18-1650.
Shah MA, Zhang X, Rossin R, Robillard MS, Fisher DR, Bueltmann T, et al. Metal-free cycloaddition chemistry driven pretargeted radioimmunotherapy using alpha-particle radiation. Bioconjug Chem. 2017;28(12):3007–15. https://doi.org/10.1021/acs.bioconjchem.7b00612.
Loke KS, Padhy AK, Ng DC, Goh AS, Divgi C. Dosimetric considerations in radioimmunotherapy and systemic radionuclide therapies: a review. World J Nucl Med. 2011;10(2):122–38. https://doi.org/10.4103/1450-1147.89780.
Flux GD, Sjogreen Gleisner K, Chiesa C, Lassmann M, Chouin N, Gear J, et al. From fixed activities to personalized treatments in radionuclide therapy: lost in translation? Eur J Nucl Med Mol Imaging. 2018;45(1):152–4. https://doi.org/10.1007/s00259-017-3859-1.
Brans B, Bodei L, Giammarile F, Linden O, Luster M, Oyen WJG, et al. Clinical radionuclide therapy dosimetry: the quest for the "holy Gray". Eur J Nucl Med Mol Imaging. 2007;34(5):772–86. https://doi.org/10.1007/s00259-006-0338-5.
Pouget JP, Lozza C, Deshayes E, Boudousq V, Navarro-Teulon I. Introduction to radiobiology of targeted radionuclide therapy. Front Med. 2015;2:12. https://doi.org/10.3389/fmed.2015.00012.
Ljungberg M, Sjogreen GK. Personalized dosimetry for radionuclide therapy using molecular imaging tools. Biomedicines. 2016;4(4) https://doi.org/10.3390/biomedicines4040025.
Li T, Ao ECI, Lambert B, Brans B, Vandenberghe S, Mok GSP. Quantitative imaging for targeted radionuclide therapy dosimetry - technical review. Theranostics. 2017;7(18):4551–65. https://doi.org/10.7150/thno.19782.
Bardiès M, Buvat I. Dosimetry in nuclear medicine therapy: what are the specifics in image quantification for dosimetry? Q J Nucl Med Mol Imaging. 2011;55(1):5–20.
Santoro L, Boutaleb S, Garambois V, Bascoul-Mollevi C, Boudousq V, Kotzki PO, et al. Noninternalizing monoclonal antibodies are suitable candidates for 125I radioimmunotherapy of small-volume peritoneal carcinomatosis. J Nucl Med. 2009;50(12):2033–41. https://doi.org/10.2967/jnumed.109.066993.
Ferrer L, Malek E, Bodet-Milin C, Legouill S, Prangere T, Robu D, et al. Comparisons of dosimetric approaches for fractionated radioimmunotherapy of non-Hodgkin lymphoma. Q J Nucl Med Mol Imaging. 2012;56(6):529–37.
Morschhauser F, Dekyndt B, Baillet C, Barthelemy C, Malek E, Fulcrand J, et al. A new pharmacokinetic model for (90)Y-ibritumomab tiuxetan based on 3-dimensional dosimetry. Sci Rep. 2018;8(1):14860. https://doi.org/10.1038/s41598-018-33160-0.
Kratochwil C, Schmidt K, Afshar-Oromieh A, Bruchertseifer F, Rathke H, Morgenstern A, et al. Targeted alpha therapy of mCRPC: dosimetry estimate of (213)bismuth-PSMA-617. Eur J Nucl Med Mol Imaging. 2018;45(1):31–7. https://doi.org/10.1007/s00259-017-3817-y.
Dewaraja YK, Schipper MJ, Shen J, Smith LB, Murgic J, Savas H, et al. Tumor-absorbed dose predicts progression-free survival following (131)I-Tositumomab Radioimmunotherapy. J Nucl Med. 2014;55(7):1047–53. https://doi.org/10.2967/jnumed.113.136044.
Schwartz J, Humm JL, Divgi CR, Larson SM, O'Donoghue JA. Bone marrow dosimetry using 124I-PET. J Nucl Med. 2012;53(4):615–21. https://doi.org/10.2967/jnumed.111.096453.
Woliner-van der Weg W, Schoffelen R, Hobbs RF, Gotthardt M, Goldenberg DM, Sharkey RM, et al. Tumor and red bone marrow dosimetry: comparison of methods for prospective treatment planning in pretargeted radioimmunotherapy. EJNMMI Phys. 2015;2(1):5. https://doi.org/10.1186/s40658-014-0104-x.
La MT, Tran VH, Kim HK. Progress of coordination and utilization of Zirconium-89 for positron emission tomography (PET) studies. Nucl Med Mol Imaging. 2019;53(2):115–24. https://doi.org/10.1007/s13139-019-00584-z.
Jauw YW, Zijlstra JM, de Jong D, Vugts DJ, Zweegman S, Hoekstra OS, et al. Performance of 89Zr-labeled-rituximab-PET as an imaging biomarker to assess CD20 targeting: a pilot study in patients with relapsed/refractory diffuse large B cell lymphoma. PLoS One. 2017;12(1):e0169828. https://doi.org/10.1371/journal.pone.0169828.
Muylle K, Flamen P, Vugts DJ, Guiot T, Ghanem G, Meuleman N, et al. Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab. Eur J Nucl Med Mol Imaging. 2015;42(8):1304–14. https://doi.org/10.1007/s00259-015-3025-6.
O'Donoghue JA, Lewis JS, Pandit-Taskar N, Fleming SE, Schoder H, Larson SM, et al. Pharmacokinetics, biodistribution, and radiation dosimetry for (89)Zr-Trastuzumab in patients with Esophagogastric cancer. J Nucl Med. 2018;59(1):161–6. https://doi.org/10.2967/jnumed.117.194555.
Ulaner GA, Lyashchenko SK, Riedl C, Ruan S, Zanzonico PB, Lake D, et al. First-in-human human epidermal growth factor receptor 2-targeted imaging using (89)Zr-Pertuzumab PET/CT: dosimetry and clinical application in patients with breast cancer. J Nucl Med. 2018;59(6):900–6. https://doi.org/10.2967/jnumed.117.202010.
Menke-van der Houven van Oordt CW, McGeoch A, Bergstrom M, McSherry I, Smith DA, Cleveland M, et al. Immuno-PET imaging to assess target engagement: experience from (89)Zr-anti-HER3 mAb (GSK2849330) in patients with solid tumors. J Nucl Med. 2019;60(7):902–9. https://doi.org/10.2967/jnumed.118.214726.
Pandit-Taskar N, O'Donoghue JA, Durack JC, Lyashchenko SK, Cheal SM, Beylergil V, et al. A phase I/II study for analytic validation of 89Zr-J591 ImmunoPET as a molecular imaging agent for metastatic prostate cancer. Clin Cancer Res. 2015;21(23):5277–85. https://doi.org/10.1158/1078-0432.CCR-15-0552.
van Es SC, Brouwers AH, Mahesh SVK, Leliveld-Kors AM, de Jong IJ, Lub-de Hooge MN, et al. (89)Zr-bevacizumab PET: potential early indicator of Everolimus efficacy in patients with metastatic renal cell carcinoma. J Nucl Med. 2017;58(6):905–10. https://doi.org/10.2967/jnumed.116.183475.
Jansen MH, van Zanten SEM V, van Vuurden DG, Huisman MC, Vugts DJ, Hoekstra OS, et al. Molecular drug imaging: (89)Zr-Bevacizumab PET in children with diffuse intrinsic pontine glioma. J Nucl Med. 2017;58(5):711–6. https://doi.org/10.2967/jnumed.116.180216.
Oosting SF, Brouwers AH, van Es SC, Nagengast WB, Oude Munnink TH, Lub-de Hooge MN, et al. 89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment. J Nucl Med. 2015;56(1):63–9. https://doi.org/10.2967/jnumed.114.144840.
Hekman MCH, Rijpkema M, Aarntzen EH, Mulder SF, Langenhuijsen JF, Oosterwijk E, et al. Positron emission tomography/computed tomography with (89)Zr-girentuximab can aid in diagnostic dilemmas of clear cell renal cell carcinoma suspicion. Eur Urol. 2018;74(3):257–60. https://doi.org/10.1016/j.eururo.2018.04.026.
den Hollander MW, Bensch F, Glaudemans AW, Oude Munnink TH, Enting RH, den Dunnen WF, et al. TGF-beta antibody uptake in recurrent high-grade glioma imaged with 89Zr-Fresolimumab PET. J Nucl Med. 2015;56(9):1310–4. https://doi.org/10.2967/jnumed.115.154401.
Even AJ, Hamming-Vrieze O, van Elmpt W, Winnepenninckx VJ, Heukelom J, Tesselaar ME, et al. Quantitative assessment of Zirconium-89 labeled cetuximab using PET/CT imaging in patients with advanced head and neck cancer: a theragnostic approach. Oncotarget. 2017;8(3):3870–80. https://doi.org/10.18632/oncotarget.13910.
Menke-van der Houven van Oordt CW, Gootjes EC, Huisman MC, Vugts DJ, Roth C, Luik AM, et al. 89Zr-cetuximab PET imaging in patients with advanced colorectal cancer. Oncotarget. 2015;6(30):30384–93. https://doi.org/10.18632/oncotarget.4672.
Makris NE, Boellaard R, van Lingen A, Lammertsma AA, van Dongen GA, Verheul HM, et al. PET/CT-derived whole-body and bone marrow dosimetry of 89Zr-cetuximab. J Nucl Med. 2015;56(2):249–54. https://doi.org/10.2967/jnumed.114.147819.
Lamberts LE, Menke-van der Houven van Oordt CW, ter Weele EJ, Bensch F, Smeenk MM, Voortman J, et al. ImmunoPET with anti-Mesothelin antibody in patients with pancreatic and ovarian cancer before anti-Mesothelin antibody-drug conjugate treatment. Clin Cancer Res. 2016;22(7):1642–52. https://doi.org/10.1158/1078-0432.CCR-15-1272.
Bensch F, van der Veen EL, Lub-de Hooge MN, Jorritsma-Smit A, Boellaard R, Kok IC, et al. (89)Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nat Med. 2018;24(12):1852–8. https://doi.org/10.1038/s41591-018-0255-8.
Niemeijer AN, Leung D, Huisman MC, Bahce I, Hoekstra OS, van Dongen G, et al. Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. Nat Commun. 2018;9(1):4664. https://doi.org/10.1038/s41467-018-07131-y.
Carrasquillo JA, Fine BM, Pandit-Taskar N, Larson SM, Fleming SE, Fox JJ, et al. Imaging patients with metastatic castration-resistant prostate cancer using (89)Zr-DFO-MSTP2109A anti-STEAP1 antibody. J Nucl Med. 2019;60(11):1517–23. https://doi.org/10.2967/jnumed.118.222844.
Ulaner GA, Hyman DM, Lyashchenko SK, Lewis JS, Carrasquillo JA. 89Zr-Trastuzumab PET/CT for detection of human epidermal growth factor receptor 2-positive metastases in patients with human epidermal growth factor receptor 2-negative primary breast cancer. Clin Nucl Med. 2017;42(12):912–7. https://doi.org/10.1097/RLU.0000000000001820.
Ulaner GA, Hyman DM, Ross DS, Corben A, Chandarlapaty S, Goldfarb S, et al. Detection of HER2-positive metastases in patients with HER2-negative primary breast cancer using 89Zr-Trastuzumab PET/CT. J Nucl Med. 2016;57(10):1523–8. https://doi.org/10.2967/jnumed.115.172031.
Pandit-Taskar N, O'Donoghue JA, Beylergil V, Lyashchenko S, Ruan S, Solomon SB, et al. 89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41(11):2093–105. https://doi.org/10.1007/s00259-014-2830-7.
Makris NE, van Velden FH, Huisman MC, Menke CW, Lammertsma AA, Boellaard R. Validation of simplified dosimetry approaches in 89Zr-PET/CT: the use of manual versus semi-automatic delineation methods to estimate organ absorbed doses. Med Phys. 2014;41(10):102503. https://doi.org/10.1118/1.4895973.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Ethics declarations
The authors report no conflict of interest with the material presented in this study. Dr. François Bénard is co-founder, director, and shareholder of Alpha-9 Theranostics, a radiopharmaceutical company. No other potential conflicts of interest relevant to this article exist.
Rights and permissions
Copyright information
© 2022 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Rousseau, J., Lau, J., Bénard, F. (2022). Radiolabeled Antibodies for Cancer Radioimmunotherapy. In: Harsini, S., Alavi, A., Rezaei, N. (eds) Nuclear Medicine and Immunology. Springer, Cham. https://doi.org/10.1007/978-3-030-81261-4_14
Download citation
DOI: https://doi.org/10.1007/978-3-030-81261-4_14
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-81260-7
Online ISBN: 978-3-030-81261-4
eBook Packages: MedicineMedicine (R0)